Novavax Sale Purchase Of Stock vs Capital Expenditures Analysis

NVAX Stock

USD 15.03 0.22 1.44%

Novavax financial indicator trend analysis is infinitely more than just investigating Novavax recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novavax is a good investment. Please check the relationship between Novavax Sale Purchase Of Stock and its Capital Expenditures accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Sale Purchase Of Stock vs Capital Expenditures

Sale Purchase Of Stock vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novavax Sale Purchase Of Stock account and Capital Expenditures. At this time, the significance of the direction appears to have strong relationship.

The correlation between Novavax's Sale Purchase Of Stock and Capital Expenditures is 0.79. Overlapping area represents the amount of variation of Sale Purchase Of Stock that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Novavax, assuming nothing else is changed. The correlation between historical values of Novavax's Sale Purchase Of Stock and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Sale Purchase Of Stock of Novavax are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Sale Purchase Of Stock i.e., Novavax's Sale Purchase Of Stock and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

0.79

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Sale Purchase Of Stock

Capital Expenditures

Capital Expenditures are funds used by Novavax to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Novavax operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most indicators from Novavax's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novavax current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.At this time, Novavax's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 442.5 M in 2024, despite the fact that Tax Provision is likely to grow to (1.8 M).

Novavax fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Net Receivables	Non Current Liabilities Total	Intangible Assets	Short Long Term Debt Total	Common Stock Total Equity	Short Term Debt	Common Stock	Long Term Debt
Total Assets		0.78	0.94	-0.56	0.87	-0.87	-0.91	0.93	0.94	0.9	0.94	0.94	0.93	0.8	0.94	0.96	0.86	0.99	0.88	0.78	-0.46	0.71	-0.41	0.67	-0.37	0.33
Other Current Liab	0.78		0.9	-0.89	0.91	-0.66	-0.9	0.93	0.72	0.88	0.75	0.68	0.84	0.55	0.85	0.9	0.91	0.7	0.55	0.66	-0.35	0.53	-0.32	0.34	-0.26	0.02
Total Current Liabilities	0.94	0.9		-0.75	0.86	-0.88	-0.92	0.96	0.94	0.87	0.93	0.92	0.88	0.83	0.89	0.98	0.86	0.92	0.76	0.67	-0.4	0.68	-0.41	0.55	-0.36	0.21
Total Stockholder Equity	-0.56	-0.89	-0.75		-0.74	0.4	0.79	-0.72	-0.53	-0.71	-0.63	-0.45	-0.69	-0.4	-0.69	-0.76	-0.75	-0.48	-0.4	-0.62	0.35	-0.56	0.21	-0.06	0.15	-0.19
Property Plant And Equipment Net	0.87	0.91	0.86	-0.74		-0.62	-0.96	0.91	0.7	0.99	0.77	0.69	0.97	0.46	0.96	0.92	1.0	0.78	0.74	0.87	-0.43	0.56	-0.36	0.46	-0.3	0.14
Net Debt	-0.87	-0.66	-0.88	0.4	-0.62		0.67	-0.82	-0.94	-0.65	-0.87	-0.94	-0.67	-0.9	-0.68	-0.8	-0.61	-0.91	-0.74	-0.38	0.22	-0.45	0.47	-0.6	0.46	-0.03
Retained Earnings	-0.91	-0.9	-0.92	0.79	-0.96	0.67		-0.93	-0.8	-0.97	-0.86	-0.77	-0.98	-0.6	-0.99	-0.97	-0.96	-0.85	-0.77	-0.89	0.5	-0.72	0.34	-0.48	0.28	-0.33
Accounts Payable	0.93	0.93	0.96	-0.72	0.91	-0.82	-0.93		0.89	0.91	0.83	0.88	0.9	0.74	0.92	0.96	0.91	0.89	0.68	0.7	-0.41	0.67	-0.4	0.65	-0.36	0.17
Cash	0.94	0.72	0.94	-0.53	0.7	-0.94	-0.8	0.89		0.73	0.92	0.99	0.77	0.95	0.8	0.9	0.69	0.97	0.76	0.57	-0.4	0.73	-0.41	0.71	-0.39	0.34
Non Current Assets Total	0.9	0.88	0.87	-0.71	0.99	-0.65	-0.97	0.91	0.73		0.81	0.72	0.99	0.49	0.98	0.93	0.99	0.82	0.79	0.89	-0.44	0.59	-0.35	0.47	-0.29	0.19
Non Currrent Assets Other	0.94	0.75	0.93	-0.63	0.77	-0.87	-0.86	0.83	0.92	0.81		0.9	0.85	0.82	0.86	0.94	0.77	0.94	0.9	0.71	-0.43	0.66	-0.44	0.45	-0.41	0.35
Cash And Short Term Investments	0.94	0.68	0.92	-0.45	0.69	-0.94	-0.77	0.88	0.99	0.72	0.9		0.76	0.94	0.79	0.88	0.67	0.98	0.77	0.55	-0.41	0.7	-0.4	0.74	-0.38	0.32
Common Stock Shares Outstanding	0.93	0.84	0.88	-0.69	0.97	-0.67	-0.98	0.9	0.77	0.99	0.85	0.76		0.55	0.99	0.95	0.97	0.86	0.84	0.92	-0.48	0.65	-0.39	0.5	-0.34	0.29
Other Current Assets	0.8	0.55	0.83	-0.4	0.46	-0.9	-0.6	0.74	0.95	0.49	0.82	0.94	0.55		0.59	0.75	0.45	0.87	0.61	0.33	-0.32	0.68	-0.36	0.67	-0.36	0.34
Other Stockholder Equity	0.94	0.85	0.89	-0.69	0.96	-0.68	-0.99	0.92	0.8	0.98	0.86	0.79	0.99	0.59		0.96	0.96	0.87	0.82	0.91	-0.5	0.7	-0.34	0.54	-0.28	0.33
Total Liab	0.96	0.9	0.98	-0.76	0.92	-0.8	-0.97	0.96	0.9	0.93	0.94	0.88	0.95	0.75	0.96		0.92	0.92	0.82	0.81	-0.47	0.73	-0.39	0.54	-0.34	0.32
Property Plant And Equipment Gross	0.86	0.91	0.86	-0.75	1.0	-0.61	-0.96	0.91	0.69	0.99	0.77	0.67	0.97	0.45	0.96	0.92		0.77	0.73	0.87	-0.42	0.55	-0.36	0.43	-0.29	0.13
Total Current Assets	0.99	0.7	0.92	-0.48	0.78	-0.91	-0.85	0.89	0.97	0.82	0.94	0.98	0.86	0.87	0.87	0.92	0.77		0.87	0.7	-0.45	0.71	-0.41	0.72	-0.38	0.36
Net Receivables	0.88	0.55	0.76	-0.4	0.74	-0.74	-0.77	0.68	0.76	0.79	0.9	0.77	0.84	0.61	0.82	0.82	0.73	0.87		0.77	-0.38	0.49	-0.46	0.41	-0.43	0.31
Non Current Liabilities Total	0.78	0.66	0.67	-0.62	0.87	-0.38	-0.89	0.7	0.57	0.89	0.71	0.55	0.92	0.33	0.91	0.81	0.87	0.7	0.77		-0.55	0.7	-0.24	0.39	-0.18	0.52
Intangible Assets	-0.46	-0.35	-0.4	0.35	-0.43	0.22	0.5	-0.41	-0.4	-0.44	-0.43	-0.41	-0.48	-0.32	-0.5	-0.47	-0.42	-0.45	-0.38	-0.55		-0.59	0.11	-0.32	0.08	-0.53
Short Long Term Debt Total	0.71	0.53	0.68	-0.56	0.56	-0.45	-0.72	0.67	0.73	0.59	0.66	0.7	0.65	0.68	0.7	0.73	0.55	0.71	0.49	0.7	-0.59		-0.12	0.65	-0.1	0.82
Common Stock Total Equity	-0.41	-0.32	-0.41	0.21	-0.36	0.47	0.34	-0.4	-0.41	-0.35	-0.44	-0.4	-0.39	-0.36	-0.34	-0.39	-0.36	-0.41	-0.46	-0.24	0.11	-0.12		-0.34	0.99	0.09
Short Term Debt	0.67	0.34	0.55	-0.06	0.46	-0.6	-0.48	0.65	0.71	0.47	0.45	0.74	0.5	0.67	0.54	0.54	0.43	0.72	0.41	0.39	-0.32	0.65	-0.34		-0.34	0.37
Common Stock	-0.37	-0.26	-0.36	0.15	-0.3	0.46	0.28	-0.36	-0.39	-0.29	-0.41	-0.38	-0.34	-0.36	-0.28	-0.34	-0.29	-0.38	-0.43	-0.18	0.08	-0.1	0.99	-0.34		0.09
Long Term Debt	0.33	0.02	0.21	-0.19	0.14	-0.03	-0.33	0.17	0.34	0.19	0.35	0.32	0.29	0.34	0.33	0.32	0.13	0.36	0.31	0.52	-0.53	0.82	0.09	0.37	0.09

Click cells to compare fundamentals

Novavax Account Relationship Matchups

Novavax fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	173.0M	1.6B	2.6B	2.3B	1.9B	1.9B
Other Current Liab	19.9M	(327.6M)	709.8M	1.5B	1.2B	1.3B
Total Current Liabilities	25.8M	322.0M	2.4B	2.5B	1.6B	1.7B
Total Stockholder Equity	(186.0M)	627.2M	(351.7M)	(634.1M)	(716.9M)	(681.1M)
Property Plant And Equipment Net	11.4M	180.0M	228.7M	400.5M	491.0M	515.5M
Net Debt	243.1M	(231.4M)	(1.1B)	(787.1M)	(298.3M)	(283.4M)
Retained Earnings	(1.4B)	(1.9B)	(3.6B)	(4.3B)	(4.8B)	(4.6B)
Accounts Payable	2.9M	54.3M	127.1M	216.5M	132.6M	139.2M
Cash	78.8M	553.4M	1.5B	1.3B	578.9M	607.9M
Non Current Assets Total	75.7M	334.3M	421.6M	555.3M	711.5M	747.0M
Non Currrent Assets Other	7.5M	13.2M	56.7M	28.5M	30.3M	31.8M
Cash And Short Term Investments	78.8M	711.0M	1.5B	1.3B	578.9M	607.9M
Common Stock Shares Outstanding	24.1M	57.6M	74.4M	78.2M	100.8M	105.8M
Liabilities And Stockholders Equity	173.0M	1.6B	2.6B	2.3B	1.9B	1.9B
Other Current Assets	93.9M	441.8M	2.1B	1.7B	226.0M	191.7M
Other Stockholder Equity	1.3B	2.5B	3.3B	3.6B	4.1B	4.3B
Total Liab	359.0M	955.3M	2.9B	2.9B	2.6B	2.7B
Property Plant And Equipment Gross	11.4M	180.0M	258.6M	447.8M	566.0M	594.3M
Total Current Assets	97.2M	1.2B	2.2B	1.7B	1.1B	1.2B
Accumulated Other Comprehensive Income	(12.5M)	7.0M	(1.4M)	(6.4M)	2.7M	2.9M
Net Receivables	7.5M	262.0M	455.0M	82.4M	297.2M	312.1M
Non Current Liabilities Total	333.2M	633.2M	538.1M	432.8M	937.1M	984.0M
Intangible Assets	6.5M	5.6M	5.7M	4.8M	4.3M	4.1M
Short Long Term Debt Total	321.9M	322.0M	454.0M	549.8M	280.6M	294.7M
Common Stock Total Equity	3.8M	324K	714K	764K	878.6K	1.3M
Short Term Debt	1.3M	322.0M	130.5M	352.1M	28.1M	43.9M
Common Stock	324K	714K	764K	868K	1.4M	1.3M
Long Term Debt	320.6M	322.0M	323.5M	166.5M	168.0M	114.6M
Inventory	(83.0M)	(166.7M)	(2.0B)	36.7M	41.7M	43.8M
Property Plant Equipment	11.4M	180.0M	228.7M	400.5M	460.6M	483.6M
Other Liab	2.6M	3.4M	175.5M	185.0M	212.8M	223.4M
Current Deferred Revenue	1.7M	273.2M	1.4B	370.1M	241.3M	140.2M
Other Assets	1.1M	5.4M	16.6M	28.5M	32.7M	34.4M
Good Will	51.2M	135.4M	131.5M	126.3M	127.5M	133.8M
Net Tangible Assets	(242.8M)	486.1M	(487.9M)	(760.4M)	(684.4M)	(650.1M)
Retained Earnings Total Equity	(1.3B)	(1.4B)	(1.9B)	(3.6B)	(3.3B)	(3.1B)
Long Term Debt Total	319.2M	320.6M	322.0M	323.5M	372.0M	234.9M
Capital Surpluse	1.1B	1.3B	2.5B	3.4B	3.9B	4.0B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
BAC	Bank of America
GM	General Motors

When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock:

How To Invest In Novavax

Details

Is Novavax Stock a good investment?

Details

What is Novavax's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Complementary Tools for Novavax Stock analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.

	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments

Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.05)

Revenue Per Share

8.726

Quarterly Revenue Growth

0.159

Return On Assets

(0.16)

Return On Equity

(8.98)

The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Novavax Sale Purchase Of Stock vs Capital Expenditures Analysis

Sale Purchase Of Stock vs Capital Expenditures

Sale Purchase Of Stock vs Capital Expenditures Correlation Analysis

Correlation Coefficient

Sale Purchase Of Stock

Capital Expenditures

Novavax fundamental ratios Correlations

Novavax Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Novavax fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Novavax Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.99	Cash
Common Stock Shares Outstanding	+ 0.99	Non Current Assets Total
Property Plant And Equipment Gross	+ 0.99	Non Current Assets Total

Other Stockholder Equity	- 0.99	Retained Earnings
Common Stock Shares Outstanding	- 0.98	Retained Earnings
Total Liab	- 0.97	Retained Earnings
Non Current Assets Total	- 0.97	Retained Earnings
Property Plant And Equipment Gross	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Property Plant And Equipment Net